酪氨酸激酶型受体、G蛋白偶联受体和离子通道型受体是细胞表面三类主要受体。
Receptor tyrosine kinases (RTK), G protein-coupled receptors (GPCR) and ion channel receptors are main cell surface receptors.
受体酪氨酸激酶样孤儿受体1（ROR1）是在B-细胞恶性肿瘤和实体瘤亚群上表达的，但不在健康B细胞或正常产后组织中表达。
Receptor tyrosine kinase-like orphan receptor-1 (ROR1) is expressed on sub-populations of B-cell malignancies and solid tumors, but not by healthy B cells or normal postpartum tissues.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
应用推荐